

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from May 2016

For further details see *PACE Bulletin* Volume 10; Number 9 (July 2016)

SUMMARY OF PACEF DECISIONS: May 2016 Update

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Abiraterone 250mg tablets (<i>Zytiga</i>) (Janssen-Cilag Ltd)	For use with prednisone or prednisolone for the treatment of: (1) metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. (2) metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.	RED Included in the <i>Lincolnshire Joint Formulary</i> for both indications subject to NICE criteria.
Doxorubicin hydrochloride liposomal pegylated concentrate for solution for infusion 2mg per 1ml (<i>Caelyx</i>) (Janssen-Cilag Ltd)	For advanced ovarian cancer when platinum-based chemotherapy has failed.	RED Approved for inclusion on the <i>Lincolnshire Joint Formulary</i> for recurrent ovarian cancer.
Gemcitabine solution for Infusion/powder for solution for infusion (non-proprietary)	For the treatment of locally advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy (in combination with carboplatin)	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for this indication.
Insulin degludec 100 iu/liraglutide 3.6mg injection (<i>Xultophy</i>) (Novo Nordisk)	For the treatment of adults with type 2 diabetes to improve glycaemic control in combination with oral glucose lowering medicines when these alone or combined with basal insulin do not provide adequate glycaemic control.	AMBER for specialist initiation only. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Paclitaxel solution for infusion (non-proprietary)	For the treatment of ovarian cancer in combination with cisplatin. For the treatment of metastatic ovarian cancer where platinum-containing therapy has failed.	RED Approved for inclusion in <i>Lincolnshire Joint Formulary</i> .
Prednisolone oral solution 5mg/5ml (<i>Prednisolone Dompe</i>)	For conditions requiring systemic corticosteroid therapy.	GREEN subject to prescribing guidance. Included in the <i>Lincolnshire Joint Formulary</i> .
Prednisolone oral solution 10mg/1ml (<i>Prednisolone Dompe</i>)	For conditions requiring systemic	RED-RED Not approved for inclusion in the

	corticosteroid therapy.	<i>Lincolnshire Joint Formulary.</i>
Propranolol 15mg tablets (<i>Pro-Banthaline</i>)	Hyperhidrosis	GREEN Included in the <i>Lincolnshire Joint Formulary</i> for this indication.
Quetiapine MR tablets 50mg, 150mg, 200mg, 300mg and 400mg (<i>Biquelle XL</i>) (Aspire Pharma)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Prescribe by brand. Standard release quetiapine preferred first line.
Quetiapine modified release tablets 50mg, 200mg, 300mg and 400mg (<i>Ebesque XL</i>) (DB Ashbourne)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Prescribe by brand. Standard release quetiapine preferred first line.
Quetiapine modified release tablets 50mg, 150mg, 200mg, 300mg and 400mg (<i>Mintreleq XL</i>) (CEB Pharma Ltd)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Prescribe by brand. Standard release quetiapine preferred first line.
Quetiapine modified release tablets 50mg, 150mg, 200mg, 300mg and 400mg (<i>Seroquel XL</i>) (Astra Zeneca Ltd)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Quetiapine modified release tablets 50mg, 150mg, 200mg, 300mg and 400mg (<i>Sondate XL</i>) (TEVA UK Ltd)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Prescribe by brand. Standard release quetiapine preferred first line.
Quetiapine modified release tablets 50mg, 200mg, 300mg and 400mg (<i>Tenprolide XL</i>) (Actavis Ltd)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Quetiapine MR tablets 50mg, 150mg, 200mg, 300mg and 400mg (<i>Zaluron XL</i>) (Fontus Health)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Prescribe by brand. Standard release quetiapine preferred first line.
Topotecan solution for infusion/powder for solution for infusion (Non-proprietary/ <i>Hycamtin</i>) (Novartis Pharmaceuticals Ltd)	For metastatic ovarian cancer when first line or subsequent treatment has failed.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Trabectedin powder for solution for infusion 250microgram and 1mg (<i>Yondelis</i>) (Pharma Mar S.A.)	For treatment of relapsed platinum-sensitive ovarian cancer (in combination with pegylated liposomal doxorubicin).	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for this indication.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP

responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care.**

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@ardengemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION